Q-omics provides the consensus-scored PAX1 profile across patient tissues and cancer cell-line models. PAX1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PAX1 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, PAX1 RNA expression shows 11,659 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, THCA, and TGCT as cancer lineages where PAX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAX1 survival associations across molecular data types. PAX1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAX1 RNA expression–survival associations across cancer types. High PAX1 expression shows unfavorable associations in UCEC, KIRC, BLCA, LIHC and LUAD, but favorable associations in LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PAX1 RNA expression.
This table summarizes PAX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PAX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAX1 shows lower tumor expression in THCA, HNSC, KIRC and KIRP and higher tumor expression in BRCA and LUSC. The THCA box plot shows higher PAX1 RNA expression in normal versus tumor tissue (log2 FC = −1.321, t-test p < 0.001).
This table shows molecular features associated with PAX1 in patient tissues and cancer cell lines. In patient samples, PAX1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PAX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
